Luxbury Ventures Llc
Community/Retail Pharmacy
440 Lehigh St, Reading
Pennsylvania, 19601-1750
484-663-5760 610-378-9000
Luxbury Ventures Llc is a Community/Retail Pharmacy in Reading, Pennsylvania. It is located at 440 Lehigh St, Reading and it's customer support contact number is 484-663-5760. The authorized person of Luxbury Ventures Llc is Fadeke Salako, B.PHARM who is Pharmacy Manager of the pharmacy and his contact number is 484-663-5760. Active license number of Luxbury Ventures Llc is PP482357 for Community/Retail Pharmacy in Pennsylvania. Luxbury Ventures Llc accepts medicare which means medicare covered patients will not be billed for any more than the Medicare deductible and coinsurance.
Luxbury Ventures Llc is a pharmacy where pharmacists store, prepare, and dispense medicinal preparations and/or prescriptions for a local patient population in accordance with federal and state law; counsel patients and caregivers (sometimes independent of the dispensing process); administer vaccinations; and provide other professional services associated with pharmaceutical care such as health screenings, consultative services with other health care providers, collaborative practice, disease state management, and education classes.
Pharmacy Details:
Luxbury Ventures Llc type, location, contact phone number and fax are as below. Patients can directly walkin to the pharmacy or can call on the below given customer support phone number for enquiries.
| Name: | Luxbury Ventures Llc |
| Type: | Community/Retail Pharmacy |
| Location: | 440 Lehigh St, Reading,
Pennsylvania, 19601-1750 |
| Phone: | 484-663-5760 |
| Fax: | 610-378-9000 |
Authorized/Official Person Profile:
Officially authorized person to contact for any management issues or complaints of this pharmacy is as below. Person's position and contact details are also mentioned below.
| Name: | Fadeke Salako |
| Credentials: | B.PHARM |
| Position: | Pharmacy Manager |
| Contact Number: | 484-663-5760 |
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of given pharmacy are as mentioned below.
| NPI Number: | 1457690026 |
| NPI Enumeration Date: | 02 Feb, 2013 |
| NPI Last Update On: | 01 Oct, 2023 |
Medical Licenses:
Organizations can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Luxbury Ventures Llc are as mentioned below.
| Specialization | License Number | State | Status | |
| Community/Retail Pharmacy | PP482357 | Pennsylvania | Primary | |
| Pharmacy | | | Secondary | |
Other Medical Identifiers:
Other legacy medical identifiers of the pharmacy such as Medicaid, Medicare PIN, NSC, UPIN etc. are mentioned as below.
| Identifier | Type | State | Issuer |
| 1028072400001 | Medicaid | Pennsylvania | |
| 2140155 | Other | | Pk |
Medicare Enrollment:
Luxbury Ventures Llc is enrolled in medicare and it's Pac Id, enrollment Id, registered name and type is as stated below.
| PAC ID: |
Enrollment ID: |
Org Name | Medicare Entity Type |
| 5991930984 | O20131029000777 | Luxbury Ventures Llc | PART B SUPPLIER - MASS IMMUNIZATION (ROSTER BILLER ONLY) |
| 5991930984 | O20140909001330 | Luxbury Ventures Llc | DME SUPPLIER - PHARMACY |
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
| Address: | 422 Augusta Dr E,
Reading, Pennsylvania |
| Zip: | 19608-2128 |
| Phone Number: | -- |
Patients can reach Luxbury Ventures Llc at
440 Lehigh St, Reading, Pennsylvania or can
call on customer care at 484-663-5760.
Comments/ Reviews:
Read all the reviews posted for Luxbury Ventures Llc below. You may also share your own experience with Luxbury Ventures Llc. Your feedback can help others make better decisions.
**Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 08 December, 2025.